← All trials
NCT04721548
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2021
- Primary completion
- Jul 30, 2023
- Completion date
- Jul 30, 2023
- First posted
- Jan 22, 2021
- Last posted
- Jan 22, 2021
- Enrollment
- 354
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eurofarma Laboratorios S.A.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.